Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An announcement from Ascletis Pharma, Inc. ( (HK:1672) ) is now available.
Ascletis Pharma Inc. announced it will present study results of its obesity treatment assets, including ASC30, ASC31, and ASC47, at ObesityWeek 2025 in Atlanta. These presentations highlight the company’s commitment to developing differentiated obesity treatments, with ASC30 being a new chemical entity with patent protection until 2044, and ASC31 and ASC47 showing promising results in preclinical studies.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$10.50 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
More about Ascletis Pharma, Inc.
Ascletis Pharma Inc. is a biopharmaceutical company focused on developing innovative treatments, particularly in the field of obesity. The company specializes in small molecules and peptide-based therapies, with a market focus on addressing metabolic disorders.
Average Trading Volume: 9,124,494
Technical Sentiment Signal: Buy
Current Market Cap: HK$9.11B
Learn more about 1672 stock on TipRanks’ Stock Analysis page.